Press Releases 2022 2021 2020 2019 all December 2, 2021 Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy November 4, 2021 Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights October 13, 2021 Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day October 1, 2021 Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression September 28, 2021 Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021 September 27, 2021 Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference September 20, 2021 Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress August 5, 2021 Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights June 25, 2021 Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress June 2, 2021 Dyne Therapeutics Announces Chief Scientific Officer Transition May 26, 2021 Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference May 14, 2021 Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA May 6, 2021 Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights April 27, 2021 New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting March 4, 2021 Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights March 4, 2021 Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer February 8, 2021 Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs January 20, 2021 Dyne Therapeutics Announces Pricing of $168 Million Public Offering January 10, 2021 Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study January 5, 2021 Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
